Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affymax, Inc.

http://www.affymax.com/

Latest From Affymax, Inc.

Learning From Danish Leaders: Openness, Engagement And Balance

Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.

Denmark Leadership

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

Hemab Raises $135m To Advance Clinical Strategy In Bleeding And Thrombotic Disorders

Hemab’s series B financing will fund its lead program, currently in Phase I/II for Glanzmann thrombasthenia, as it moves into pivotal testing plus at least one other asset heading into the clinic.

Financing Blood & Coagulation Disorders

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds

Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

Scrip Asks Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register